Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function
in patients with asthma. Roflumilast will be administered orally once daily. The study
duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The
study will provide further data on safety, tolerability, and effectiveness of roflumilast.